Printer Friendly

BIO-VASCULAR ANNOUNCES FIRST PROFITABLE YEAR

 BIO-VASCULAR ANNOUNCES FIRST PROFITABLE YEAR
 ST. PAUL, Minn., Dec. 11 /PRNewswire/ -- Bio-Vascular, Inc.


(NASDAQ: BVAS), a St. Paul-based company, announced today the first profitable year in the company's history. Sales for the year ended Oct. 31, 1991, were $3,375,507, an increase of 21.8 percent over sales of the previous year of $2,770,654. Net income for the year ended Oct. 31, 1991, was $25,515 and compares to a loss of $179,842 for the year ended Oct. 31, 1990. Income for the year ended Oct. 31, 1991, of $25,515 included an extraordinary gain on the early extinguishment of debt of $59,031.
 Bio-Vascular, Inc. is a manufacturer and distributor of proprietary consumable medical products used in cardiac and vascular surgery. Bio- Vascular's common stock is traded on the national over-the-counter market under the symbol BVAS.
 BIO-VASCULAR, INC.
 Quarter Ended
 10/31/91 10/31/90
 Net sales $839,122 $819,023
 Net income $49,366 $60,413
 Net income per common share -- $.02
 Weighted average number of 5,303,837 3,857,650
 common shares outstanding
 Fiscal Year Ended
 10/31/91 10/31/90
 Net sales $3,375,507 $2,770,654
 Net income (loss) $25,515 $(179,842)
 Net income (loss) per common share -- $(.05)
 Weighted average number of
 common shares outstanding 5,264,040 3,793,814
 -0- 12/11/91
 /CONTACT: John H. Darnall or M. Karen Gilles of Bio-Vascular, 612-631-3529/
 (BVAS) CO: Bio-Vascular, Inc ST: Minnesota IN: MTC SU: ERN


KH -- MN011 -- 1485 12/11/91 12:49 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 11, 1991
Words:260
Previous Article:EXTENDING THE REACH OF ESCON; IBM AND AT&T PARADYNE FORMALIZE AGREEMENT TO DEVELOP CHANNEL EXTENSION PRODUCTS
Next Article:AMERICAN PACIFIC BREAKS GROUND FOR SODIUM AZIDE PLANT
Topics:


Related Articles
BIO-VASCULAR ANNOUNCES REGULATORY SUBMISSION FOR BIOFLOW(R) SMALL DIAMETER GRAFT
BIO-VASCULAR REPORTS FIRST QUARTER GAINS IN SALES AND NET INCOME
BIO-VASCULAR REPORTS GAINS IN FIRST QUARTER SALES, NET INCOME
BIO-VASCULAR REPORTS FOURTH QUARTER RESULTS
BIO-VASCULAR REPORTS 1ST QUARTER RESULTS
BIO-VASCULAR REPORTS REVENUE INCREASES FOR 4TH QUARTER, YEAR
BIO-VASCULAR REPORTS PROFIT IN SECOND QUARTER
EPIX Medical Presents at BIO CEO & Investor Conference - AngioMARK, Lead Contrast Agent for MRI, in Late Stage Trials -.
Orbus Announces Start Of HEALING Clinical Program With First Coronary Bio-Engineered Stent To Inhibit Restenosis.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters